Oxford Gene Technology Ltd. v. Affymetrix, Inc.

I'll research this case across multiple sources to verify the facts before drafting.

Good foundation. Now let me verify patent details, the judge, settlement terms, and modern context.

Let me verify the judge, the Markman ruling, OGT's licensing campaign, and the parties' later corporate history.

Overview and Background — Oxford Gene Technology Ltd. v. Affymetrix, Inc., No. 1:99-cv-348 (D. Del.)

Parties. The plaintiff, Oxford Gene Technology Ltd. ("OGT"), is an Oxford, England–based company "set up to exploit the DNA microarray patents of Professor [Sir] Edwin Southern" (Bioprocess Online, June 7, 1999), the Oxford University biochemist famous for the Southern blot. OGT was founded by Southern, who was its principal shareholder, and it was a hybrid entity rather than a pure holding vehicle: its core business was licensing the "Southern patents," but it also ran an operating arm producing custom-synthesized microarray content for pharma, agbio, and genomics customers (OGT press release, Nov. 10, 2000, via Silicon Investor). In other words, this is a university spin-out/technology-transfer monetization model, not a modern mass-filing PAE. The defendant, Affymetrix, Inc., then headquartered in Santa Clara, California, was the market leader in DNA microchips — the English Court of Appeal described it as "a substantial Delaware corporation based in eastern California… a market leader in the production of DNA microchips" (Oxford Gene Technology Ltd v Affymetrix Inc & Ors [2000] EWCA Civ 253 ¶2).

The accused technology and the patent. OGT alleged that Affymetrix's GeneChip system infringed U.S. Patent No. 5,700,637. The GeneChip system comprised "disposable DNA probe arrays that contain gene sequences on a chip, reagents for use with the probe arrays, a scanner, and other instruments to process them" (CBS MarketWatch, Nov. 2000) — high-density arrays built by Affymetrix's light-directed (photolithographic) in situ synthesis. The '637 patent, "Apparatus and Method for Analyzing Polynucleotide Sequences and Method of Generating Oligonucleotide Arrays," names Edwin Southern as sole inventor, issued December 23, 1997, and claims priority to a May 3, 1988 UK filing (PCT filed May 2, 1989; U.S. App. No. 08/230,012, filed April 19, 1994) (FreePatentsOnline; RPX Insight). Notably, it issued to Isis Innovation Limited, Oxford University's tech-transfer arm, and was later held by OGT (Google Patents lists the '637 under Oxford Gene Technology Ltd. as a related-family member). In one line: the '637 is a pioneer patent on making and using DNA microarrays — claim 1 covers a method of generating an array of oligonucleotides of chosen lengths by step-wise coupling of nucleotide precursors into "discrete cell locations" on a support, and claims 6–8 cover analyzing polynucleotides by hybridizing labeled material to a support segregated into defined cells bearing in-situ-synthesized oligonucleotides (RPX Insight claim text). Only the '637 was asserted in Delaware; the family also included U.S. 6,054,270 and the European counterpart EP 0 373 203, which OGT asserted in parallel UK proceedings (Affymetrix Form 10-Q, citing the Delaware action as alleging infringement of "United States Patent 5,700,637" (CapEdge 10-Q)).

Procedural posture, venue, and why it matters. OGT filed in the U.S. District Court for the District of Delaware on June 4, 1999, before Judge Joseph J. Farnan, Jr. (MoreLaw case entry), with Richard K. Herrmann (Blank Rome) as Delaware counsel for OGT, Jack B. Blumenfeld (Morris Nichols) for Affymetrix, and a Kirkland & Ellis trial team led by Mark Pals (Kirkland & Ellis press release, Nov. 2000); Affymetrix's U.S. litigation counsel included Orrick, Herrington & Sutcliffe and Sullivan & Cromwell (EWCA Civ 253 ¶9). Delaware venue was natural and, for OGT, strategically decisive: Affymetrix was a Delaware corporation, and the district was already the nation's premier patent forum. Affymetrix countered on June 17, 1999 with a declaratory-judgment action in the N.D. Cal. seeking a ruling that the Beckman acquisition gave it a valid license — that case "was transferred and consolidated with the Delaware action," so OGT held its chosen forum (Affymetrix 10-Q). The court phased the trial into three parts — (1) infringement/willfulness, (2) defenses (invalidity, non-enablement, patent misuse, inequitable conduct, antitrust), and (3) damages. On November 6, 2000 the court issued its Markman order and began phase 1; the eight-person jury returned a verdict on Friday, November 10, 2000: no literal infringement and no willfulness, but infringement under the doctrine of equivalents (Kirkland; Nature Biotechnology 18:1230 (2000)). The court also confirmed Affymetrix held a valid license to the '637 as of no earlier than June 1, 1999, by virtue of its purchase of Beckman Coulter's microarray business — adopting the UK Court of Appeal's November 2, 2000 ruling in the parallel UK case (EWCA Civ 253; OGT press release, Nov. 10, 2000). Phases 2 and 3 (OGT claiming up to "$40 million in damages," per Law.com, though Nature Biotechnology reported OGT had initially sought ~$300 million) were never tried.

Why the case is notable. Four things stand out. (1) It was the first blockbuster test of a foundational "pioneer" microarray patent, pitting the academic inventor of array hybridization against the company that industrialized it. The jury's failure to find literal infringement while finding equivalents is a classic illustration of the doctrine of equivalents rescuing a pioneering claim from a differently-implemented later technology — and it was decided only months before the Supreme Court's Festo decision (2002) narrowed DOE via prosecution history estoppel. (2) It is a leading example of transatlantic parallel litigation, where a UK appellate ruling on whether a patent license transferred in an asset sale effectively dictated the U.S. license defense, and OGT's planned House of Lords appeal became a settlement chip (Science 291:2535 (2001)). (3) It illustrates the "license by acquisition" defense — Affymetrix bought Beckman Coulter's array business rather than continue negotiating a license from OGT, prompting OGT's suit. (4) The market and NPE-monetization context was significant: OGT told counsel it wanted Affymetrix forced to license competitors, and had demanded a 10% royalty on all future Affymetrix array sales (IEEE Spectrum, March 2001); the three-day verdict knocked ~9% off Affymetrix's halted shares before the license ruling restored them, and the March 23, 2001 global settlement — dropping all U.S. and UK suits and the EPO oppositions, with no patent transfers — was booked as a $19 million charge in Affymetrix's Q4 2000, with a smaller Q1 2001 legal-fee charge; shares rose 14–18% (NYT, Mar. 27, 2001; Nature Biotechnology 19:399 (2001)). This was one of several simultaneous microarray patent wars around Affymetrix (Hyseq, Incyte/Synteni, PE Corporation, Nanogen/Motorola); OGT later ran a second licensing/enforcement campaign on the sibling '270 patent against Nanogen, BD Biosciences Clontech, Genomic Solutions, PerkinElmer, Axon Instruments, and BioDiscovery beginning in December 2002 (Pharmacogenomics 4(5):623 (2003), IP retrospective).

On IPR linkage specifically: there is none, by chronology. The case closed in 2001, more than a decade before the AIA created IPR/CBM proceedings at the PTAB; RPX Insight records zero petitions and zero reexaminations for the '637. The parallel administrative challenge functioned through the EPO opposition to EP 0 373 203 (pending since 1995) and OGT's UK revocation actions against Affymetrix's EP (UK) 0 619 321 and GB 2248840 — all withdrawn in the settlement (Nature Biotechnology 19:399; CapEdge 10-Q, noting OGT withdrew its opposition to EP 0-619-321). The '637 has since expired.

Sourcing caveats. (a) Docket-sheet-level detail (entry numbers, exact dismissal order) could not be verified because PACER was not accessible in this session; the dates above come from contemporaneous party SEC filings and press coverage. (b) The verdict date is reported inconsistently: the weight of sources (Kirkland, OGT's own release, Nature Biotechnology, CBS MarketWatch, IEEE Spectrum) gives Friday, November 10, 2000; MoreLaw lists a "date decided" of November 9, 2000 and one Law.com item says November 17 — the latter appears erroneous. (c) The damages figures conflict ($40M "maximum" claimed in phase 3 vs. a reported ~$300M initial demand), and I could not reconcile them. (d) I could not verify in this session the later corporate fates of the parties (e.g., Affymetrix's 2016 acquisition by Thermo Fisher Scientific, and OGT's later ownership); those are widely reported but unconfirmed by the sources reviewed here, so treat them as unverified. (e) Affymetrix's annual reports described the license as "confirmed" by the Delaware court following the UK appeal; the precise pre-June-1, 1999 infringement/damages window was never adjudicated because the case settled.

I'll research this case across the docket, opinions, and press sources.

I have strong initial coverage. Now let me dig into the docket, UK parallel rulings, and any PTAB/reexamination activity.

Now let me get the actual docket and any district court opinions (JMOL, Markman).

Key Legal Developments — Oxford Gene Technology Ltd. v. Affymetrix, Inc., No. 1:99-cv-00348 (D. Del.)

Judge: Joseph J. Farnan, Jr. · Patent: U.S. 5,700,637 ("Apparatus and method for analysing polynucleotide sequences and method of generating oligonucleotide arrays," issued 1997-12-23) · Disposition: global settlement announced 2001-03-23; all U.S. and UK actions withdrawn.

Counsel of record: OGT — Richard K. Herrmann (Blank, Rome, Comisky & McCauley, Wilmington); trial team from Kirkland & Ellis (Mark Pals, Bob Krupka, Bryan Hales, Marc Sernel, Ken Bridges, Alex DeNeve, Laura TenBroeck, Kirstin Larson, Cindy Ahn, Jim Shimota). Affymetrix — Jack B. Blumenfeld (Morris, Nichols, Arsht & Tunnell); U.S. patent litigation handled by Orrick, Herrington & Sutcliffe (William Anthony, Elizabeth Howard), with Sullivan & Cromwell (Michael Steinberg) coordinating; GC Vern Norviel.

---

1. Pre-suit background (the license dispute that drove everything)

The U.S. case cannot be understood without the underlying license chain, which was litigated in parallel in the UK:

• Oxford University's tech-transfer arm, Isis Innovation Ltd., granted Beckman Coulter an exclusive license to the Southern patent rights on 1991-04-17.
• An amended license dated 1996-04-17 made the grant non-exclusive and added two provisions that became the crux of the dispute: a "Licensee Consortium" clause (clause 9.2) obligating Isis not to unreasonably withhold a license to a consortium member, and a successor/assignment clause (clause 16.2) allowing Beckman's rights to "pass to any person… succeeding to its business in products licensed hereunder."
• 1997-07-07: Isis assigned the patents and the Beckman license to OGT. The '637 patent issued 1997-12-23.
• Late 1997 – 1998: OGT/Affymetrix license negotiations produced heads of agreement in December 1997 (reportedly a $20M signing fee at 5% royalty, plus a cross-license to OGT), but the deal collapsed in July/August 1998. Instead, on 1998-07-29 Beckman and Affymetrix signed a Consortium Agreement, an Asset Purchase Agreement, and a "Precedence Letter," and on/around 1999-06-05 Affymetrix acquired Beckman's microarray business.

2. Filing and initial pleadings (1999)

• 1999-06-04 (US) / 1999-06-01 (UK claim form): OGT filed suit in the District of Delaware alleging infringement of the '637 patent by Affymetrix's GeneChip products, seeking an injunction and damages. It simultaneously sued in the English High Court on the European counterpart, EP 0 373 203, naming Affymetrix Inc., Affymetrix UK Ltd., and Beckman Coulter; that action sought a declaration that OGT was not obliged to license Affymetrix and an injunction against infringement.
• 1999-06-17: Affymetrix filed a declaratory-judgment complaint in the N.D. Cal. seeking a declaration that it held a valid license and therefore did not infringe. Per Affymetrix's SEC disclosure, that case was transferred and consolidated with the Delaware action — the principal early venue/transfer fight, resolved in OGT's forum.
• Answer/counterclaims: Affymetrix denied infringement and moved to amend its answer to (i) challenge the validity of the '637 patent and (ii) add a patent misuse defense and counterclaims, plus defenses of unenforceability through inequitable conduct and antitrust violations arising from OGT's relationships with Affymetrix competitors (Agilent, Incyte). Press reports confirm the antitrust/misuse theory was expressly teed up after the verdict.
• In the UK, Affymetrix counterclaimed for revocation, and OGT gave notice of intention to amend the patent under s.75 of the Patents Act 1977 (Sept. 1999). On 1999-07-30, Laddie J ordered the license issues tried as preliminary issues.

3. Pre-trial motions of substance

• U.S. — transfer/consolidation of Affymetrix's N.D. Cal. DJ action into D. Del. (granted; per 10-Q disclosure).
• U.S. — second Delaware action: On 2000-06-21, Affymetrix and Beckman filed a separate suit in D. Del. seeking to enjoin OGT from terminating the Beckman license. At the TRO hearing OGT agreed not to terminate pending decision; a preliminary-injunction hearing was held 2000-07-21. The court never ruled — the motion was overtaken by the UK Court of Appeal's November 2000 decision and then by settlement.
• UK — stay motion denied: On 2000-04-19, the High Court (Chancery Division, Patents Court) denied OGT's request for a stay of the infringement, validity, and amendment issues.
• No motion to dismiss or stay pending IPR: IPR/PGR did not exist in this era (AIA review proceedings began 2012-09-16), so there was no PTAB stay practice. I found no reported summary-judgment ruling of substance in this case; the case instead proceeded to a trifurcated trial (Phase 1 infringement/willfulness; Phase 2 invalidity, misuse, unenforceability; Phase 3 damages), which effectively deferred the dispositive issues.

4. Markman / claim construction

• 2000-11-06: Judge Farnan issued an order construing terms of the asserted claims, following a Markman hearing. This is confirmed in Affymetrix's SEC quarterly disclosure and in press coverage of the trial. Note: I was unable to locate the specific constructions or a published Markman opinion in the sources available; the order appears to be docket-only and was contemporaneous with the start of trial.

5. Discovery milestones with strategic significance

• UK privilege/amendment-disclosure battle (a genuinely significant discovery fight): After OGT moved to amend the EP(UK) patent under s.75, the court ordered disclosure of documents bearing on the court's discretion to allow amendment. Affymetrix sought to widen disclosure to its U.S. litigation counsel (Orrick) and U.S. coordinator (Sullivan & Cromwell), which raised the question whether OGT's English legal privilege (and any U.S. privilege) had been waived.
  • 2000-08-01: Pumfrey J held privilege had been lost in England but exercised discretion to confine use of the documents to the amendment proceedings, refusing wider disclosure (judgment given in private).
  • 2000-11-23: Court of Appeal (Brooke and Sedley LJJ), Oxford Gene Technology Ltd v Affymetrix Inc [2000] EWCA Civ 253, allowed Affymetrix's appeal on the privilege/waiver principles, holding (among other things) that a patentee seeking amendment is not obliged to waive privilege, and that the question of waiver is for the court on justice-and-fairness grounds — a decision of continuing practitioner significance on privilege in amendment/opposition practice.
• U.S. discovery: Affymetrix's filings acknowledge the case involved "a substantial amount of discovery," and the misuse/antitrust defenses turned on OGT's dealings with Affymetrix competitors (Agilent funded much of OGT's litigation; Incyte was a licensee). I could not source specific U.S. discovery cutoff dates or discovery orders from available public materials.

6. The parallel UK merits rulings (which the Delaware court then adopted)

• April 2000 (High Court, Jacob J): On the preliminary issues, the court held OGT was not obliged to grant Affymetrix a license and that Affymetrix was not licensed. Beckman did not have a "business in products" within clause 16.2 (a research operation with no commercial products), and the Affymetrix–Beckman arrangement was not a "Licensee Consortium" under clause 9.2. Affymetrix's share price fell ~13% ($19).
• 2000-10-16/17: Court of Appeal heard the appeal.
• 2000-11-02: The Court of Appeal (Aldous, Brooke, Sedley LJJ), Oxford Gene Technology Ltd v Affymetrix Inc & Ors [2000] EWCA Civ 272, reversed: Affymetrix's purchase of Beckman's microarray business did transfer the license; it rejected the consortium theory; it refused permission to appeal to the House of Lords; and it expressly left the effective date of the license to the trial judge. Affymetrix stock jumped 32% ($19.36) on the news. This is the ruling the Delaware court then accepted as establishing Affymetrix's license, and OGT announced it would petition the House of Lords directly.
• 2000-11-23: The separate privilege appeal, [2000] EWCA Civ 253 (above).
• Dropped/parallel actions: OGT's UK revocation actions against Affymetrix's GB 2,248,840 and EP(UK) 0 619 321 (listed for March 2001 hearing), and OGT's EPO opposition to EP 0 619 321, were all still pending when the case settled.

7. Trial (Phase 1, infringement/willfulness) and verdict

• 2000-11-06 to 11-08/09: Phase 1 trial on infringement and willfulness before Judge Farnan in Wilmington; eight-person jury.
• 2000-11-10: Verdict for OGT:
  • No literal infringement.
  • No willful infringement (which killed OGT's request for treble damages).
  • Infringement under the doctrine of equivalents as to Affymetrix's manufacture and use of GeneChip products.
  • The court confirmed Affymetrix holds a valid license (the U.S. court giving effect to the UK Court of Appeal ruling on the license; the license date was identified as no earlier than June 1, 1999). Sourcing caveat: the existing case summary states the jury found a license as of 1999-06-01; contemporaneous press and the 10-Q attribute the license holding to the court and state the date "remains to be determined." Treat the precise date as contested in the record.
• Damages exposure: OGT's damages-phase claim was reported at up to $40 million (LA Times/Wired), with earlier pre-trial estimates of up to ~$300 million; the theory was ~17 months of infringement (1997-12-23 issuance to the June 1, 1999 license date), with OGT contending the period could be as long as nearly three years.

8. Post-trial motions

• Affymetrix moved for JMOL to overturn the doctrine-of-equivalents verdict (motions pending and undecided at the time of settlement, per the 10-Q and Law.com).
• OGT sought a retrial on willfulness, arguing the judge gave the jury improper instructions (per IEEE Spectrum, March 2001).
• Phase 2 (invalidity on prior art and non-enablement, patent misuse, inequitable conduct, antitrust) and Phase 3 (damages) had not been scheduled/tried when the case settled. No fee award, JMOL ruling, or new-trial ruling was ever issued — all were mooted by settlement.

9. Settlement and final disposition

• 2001-03-23 (announced late Friday; Affymetrix notice posted 2001-03-26): Global settlement. The parties withdrew all U.S. and UK lawsuits and all EPO opposition/interference proceedings between them; OGT dropped its planned House of Lords appeal; Affymetrix retained its license to the Southern patents. Terms were undisclosed.
• Financial terms as disclosed: Affymetrix recorded an approximate $19 million charge for the settlement plus a smaller legal-fee amount (per its SEC notice and Science/Nature Biotechnology reporting); Affymetrix shares rose ~14% to just over $30. OGT characterized the outcome as "very satisfactory"; CEO Andy Millar and Prof. Sir Edwin Southern both framed it as clearing the way for OGT's licensing program.
• Aftershocks: In June 2004, Affymetrix agreed to pay OGT $62.5 million to buy out its remaining obligations under the 2001 settlement (GenomeWeb). And in December 2002, OGT filed new D. Del. infringement suits against seven companies (BD Biosciences Clontech, Nanogen, Axon Instruments, Biodiscovery, Mergen, PerkinElmer Life Sciences, Genomic Solutions) — this time on the later-issued U.S. 6,054,270 ('270) patent, which was expressly not part of the Affymetrix case.

10. Parallel administrative/PTAB-type proceedings

• There are no PTAB IPR/PGR/CBM proceedings on the '637 patent. The America Invents Act trial proceedings did not exist until 2012-09-16, more than a decade after this case settled. Any characterization of a "stay pending IPR" or PTAB parallel proceeding would be anachronistic here.
• The real parallel administrative proceeding was at the EPO: EP 0 373 203, granted 1994-08-31, was under opposition from 1995 by seven parties including Affymetrix, Roche, Abbott and Nanogen. The EPO Opposition Division upheld the patent with amendments in November 2001 (after this settlement); appeals followed, and the Technical Board of Appeal upheld the patent again in October 2005 (OGT press release, 2005-10-18), amendments having narrowed coverage to arrays of oligonucleotides covalently attached to a smooth impermeable glass surface. That decision was final within the EPO. Affymetrix became a licensee under the '203 patent.
• U.S. reexamination: The related '270 patent — not the '637 — was the subject of ex parte reexaminations 90/008,428 (filed 2007-01-16), 90/008,830 (2007-09-04), and 90/010,020 (2007-10-09), resulting in a reexamination certificate on 2009-08-18. I found no reexamination, interference, or other USPTO proceeding on the '637 patent itself. (Affymetrix's mid-2000 SEC filings do reference an unrelated Stanford–Affymetrix interference involving the '305/'992 patents and Hyseq/Incyte — not OGT.)

---

Practical takeaways

1. The verdict was a split decision that never got finalized. OGT won infringement only under the doctrine of equivalents (no literal infringement, no willfulness), while Affymetrix won the license issue by virtue of a foreign (UK) judgment that the Delaware court adopted. That combination sharply capped damages to a pre-June-1999 window and exposed OGT's DOE win to a pending JMOL motion.
2. The decisive forum was London, not Wilmington. The license question — whether Beckman's 1991/1996 license traveled with the sale of Beckman's microarray "business" — was resolved by the English Court of Appeal on 2000-11-02 under clause 16.2 of the Isis–Beckman agreement, and the Delaware court deferred to it. The U.S. validity/misuse/unenforceability phases, where Affymetrix had real leverage, were never tried.
3. The case generated a durable privilege precedent in the UK: [2000] EWCA Civ 253 (patentee seeking s.75 amendment need not waive privilege; waiver is a question for the court on justice-and-fairness grounds).
4. Settlement was cheap relative to the stakes: ~$19M charge in 2001 versus claimed exposure of $40M in the damages phase (and earlier ~$300M rhetoric), with a further $62.5M buyout in 2004.

Sourcing notes and gaps

• Well sourced: filing dates; the UK preliminary-issue and Court of Appeal rulings ([2000] EWCA Civ 272, 2000-11-02; [2000] EWCA Civ 253, 2000-11-23); the 2000-11-06 Markman order and 2000-11-10 verdict (Affymetrix SEC 10-Q disclosure; Kirkland & Ellis press release; LA Times/Wired/MarketWatch); the 2001-03-23 settlement and $19M charge (LA Times; Science, 2001-03-30; Nature Biotechnology 19:399 (2001); BioWorld).
• Not well sourced / could not confirm: the specific Markman constructions; the exact docket entry numbers and the stipulation/order of dismissal; the precise date the license was found effective in the U.S. record (jury vs. court, and whether June 1, 1999 was a finding or an assumption); any U.S. summary-judgment or dismissal rulings; and U.S. discovery cutoffs. MoreLaw lists a verdict date of 2000-11-09 while Kirkland reports trial Nov. 6–9 with the verdict returned Nov. 10 — contemporaneous reporting favors 2000-11-10. PACER/RECAP would be needed to confirm docket numbers and the dismissal entry.

I'll research the counsel of record for Oxford Gene Technology Ltd. in this Delaware action.

Good leads. Let me dig deeper into the docket and counsel team.

Strong findings. Let me verify the docket and individual attorneys.

Bottom line

I could not pull the actual PACER docket sheet for 1:99-cv-00348, and this 1999–2001 docket predates PACER's modern electronic filing era (the first ECF entries in Delaware appear around 2001–2004, and the 2006 Clerk's letter in this very case survives only as a scanned image). So the appearance list below is reconstructed from a jury-verdict reporter entry, a contemporaneous Kirkland & Ellis press release, and a 2006 Clerk's-office letter bearing this case number. Attorneys who appeared but were never named in those sources (e.g., in sealed filings, pro hac vice motions, or notices of withdrawal) would not show up here, and I am not inventing them.

---

Plaintiff's counsel of record — OGT (U.S. action)

Lead trial counsel — Kirkland & Ellis LLP (Chicago)

Kirkland & Ellis issued a press release on the November 10, 2000 phase-one verdict identifying its OGT trial team by name. As issued, the release does not assign "lead" vs. "associate" labels, so the role designations below are inferred from order of listing and known seniority.

Source: Kirkland & Ellis press release, "OGT Defeats Affymetrix in Court Over Patent Infringement Suit" (Nov. 2000), https://www.kirkland.com/news/press-release/2000/11/ogt-defeats-affymetrix-in-court-over-patent-infrin.

Delaware counsel (local counsel of record)

Sources:

• MoreLaw verdict report, Oxford Gene Tech Ltd v. Affymetrix Inc., No. 99-cv-348 (D. Del.), https://www.morelaw.com/verdicts/99-cv-348/DE/11568/ — "Plaintiff's Attorney: Richard K. Herrmann of Blank, Rome, Comisky & McCauley, Wilmington, Delaware."
• Clerk's letter, Oxford Gene Technology, Ltd. v. Affymetrix, Inc., C.A. No. 99-348 JJF, D.I. 354 (filed Jan. 24, 2006), addressed to Richard K. Herrmann (Morris, James, Hitchens & Williams) and Maryellen Noreika (Morris, Nichols, Arsht & Tunnell) re: return/disposition of exhibits under D. Del. L.R. 79.1(b)(2). The Noreika/Morris Nichols side of that letter is the defendant's firm (Jack B. Blumenfeld of Morris Nichols is the reported Affymetrix counsel), not OGT's.

Client-side / UK counsel (not U.S. counsel of record)

• Chris Shelley, solicitor at Manches (Oxford/London), was publicly identified in IEEE Spectrum as the lawyer representing OGT and speaking for the company about the litigation (https://spectrum.ieee.org). He is UK-side counsel, not counsel of record in Delaware.
• Alastair Wilson QC and Tamsin Holman, instructed by Manches, appeared for OGT in the parallel UK Patents Court proceeding, Oxford Gene Technology Ltd v. Affymetrix Inc. [2000] EWHC Patents 111 (Jacob J., Apr. 18, 2000); Mr. Prescott QC argued for OGT in the related privilege appeal, [2000] EWCA Civ 253 (Nov. 23, 2000). These are English barristers, not admitted in the Delaware action.
• I found no documented in-house counsel for OGT in the U.S. action.

---

Caveats and verification gaps

1. No PACER/docket confirmation obtained. I could not retrieve the attorney appearance entries for 1:99-cv-00348 directly. My party-side attribution rests on (a) the MoreLaw verdict reporter's plaintiff/defendant attorney listing and (b) the Kirkland press release, both of which are secondary but contemporaneous and mutually consistent.
2. Role granularity for the Kirkland team is unknown. The firm did not designate lead vs. supporting counsel; only Mark Pals is inferable as first chair from ordering. Do not treat the other nine as confirmed "of counsel" or "associate" without the docket.
3. Firm transitions over the 2006 life of the case. Herrmann appears as Blank Rome in the 2000 verdict report but as Morris James in the 2006 Clerk's letter, so the docket's counsel listing likely changed post-trial. Any withdrawal/substitution entries (if filed) would be on the docket I could not retrieve.
4. Pro hac vice admissions are not captured. Out-of-state Kirkland attorneys would each have needed a D. Del. pro hac vice motion; I did not find those entries.
5. Related but distinct OGT litigations. Blank Rome LLP appears as OGT's Delaware counsel in the sibling OGT cases (OGT v. Mergen Ltd., C.A. No. 02-1695; OGT v. Telechem, C.A. No. 04-013; OGT v. Nanogen, C.A. No. 02-1687), and Michael Best & Friedrich LLP (Chicago) represented OGT in OGT v. Motorola, N.D. Ill. No. 02-9344. These are not this case and should not be blended into the 99-348 appearance list.
6. Defendant-side context (for boundary clarity only, not the answer): Affymetrix's Delaware counsel was Jack B. Blumenfeld of Morris, Nichols, Arsht & Tunnell; its U.S. patent litigation was conducted by Orrick, Herrington & Sutcliffe (William Anthony and Elizabeth Howard, per the UK Court of Appeal judgment), with Michael Steinberg of Sullivan & Cromwell as U.S. coordinator, and in-house Vern Norviel (SVP/GC) and Philip McGarrigle (in-house patent counsel).

If you need a formally verified list, the reliable next step is the D. Del. docket itself (CM/ECF or the archived paper docket at the Wilmington clerk's office) — the 1999–2001 filings in this case are largely paper and may not be uniformly available online.

I'll research the docket and counsel appearances for this case.

Initial hits give me the defendant's Delaware counsel. Let me dig deeper into the full docket and any out-of-state lead counsel.

Excellent — the UK Court of Appeal judgment names Affymetrix's U.S. counsel. Let me verify against the Delaware docket and other sources.

Counsel of Record for the Defendant — Affymetrix, Inc.

Oxford Gene Technology Ltd. v. Affymetrix, Inc., No. 1:99-cv-00348-JJF (D. Del.) (Judge Joseph J. Farnan, Jr.)

Sourcing caveat up front: I was not able to pull the raw PACER/CourtListener docket sheet for this 1999 filing in this session (the electronic docket begins largely post-2001, and search access was exhausted). The roster below is reconstructed from (a) the England & Wales Court of Appeal judgment in the parallel UK action, which expressly names Affymetrix's U.S. litigation team, (b) contemporaneous press reports and a Delaware Clerk's Office letter in the case file, and (c) firm-stamped documents filed in the case. Where a role is inferred rather than stated in a primary source, I say so.

---

Delaware counsel of record — Morris, Nichols, Arsht & Tunnell LLP (Wilmington, DE)

Note on role labeling: In Delaware practice the in-state firm is often styled "local counsel" while an out-of-state firm does the substantive work. Here Morris Nichols filed substantive briefs (motions, summary-judgment oppositions) in its own name, so its attorneys were counsel of record, not merely nominal local counsel.

---

Out-of-state lead trial counsel — Orrick, Herrington & Sutcliffe LLP

Caveat: I could not verify the specific office (San Francisco/New York) each worked from, nor identify additional Orrick associates who may have entered appearances pro hac vice.

---

Coordinating U.S. counsel — Sullivan & Cromwell LLP

---

In-house counsel — Affymetrix, Inc.

Note: Affymetrix later used different in-house IP counsel of record — Michael J. Malecek, Daniel R. Reed, Andrea L. Gross, Stephen C. Holmes, George C. Yu — but those appearances are from the separate Affymetrix v. Illumina litigation (2004–2007) and should not be attributed to CA No. 99-348.

---

Related but not U.S. counsel of record

• In the parallel UK proceedings (HC 1999 02517 / HC 1999 04645), Affymetrix was represented by Bristows (solicitors) with Richard Miller QC, Richard Meade and G. Pritchard (later P. Leaver QC and C. Bingham) — e.g., [2000] EWCA Civ 272 and [2000] EWCA Civ 253. These are English counsel and should not be confused with the Delaware roster.
• Plaintiff OGT's Delaware counsel was Richard K. Herrmann (then of Blank Rome, later Morris James Hitchens & Williams), with Blank Rome LLP filing OGT's briefs. That is the plaintiff's side — included here only to prevent confusion with the Morris Nichols defendant team.

---

Explicit gaps / what I could not confirm

1. No appearance list from the docket itself. I did not retrieve the D.I.-by-D.I. appearance entries or pro hac vice orders; the individual attorneys above are identified from the UK Court of Appeal judgment, the Clerk's letter (D.I. 354), press coverage, and firm-stamped filings — not from a PACER docket printout.
2. Many filings were sealed or withheld as privileged. The EWCA judgment notes Affymetrix documents were withheld/with privileged claims, and the March 2001 global settlement was confidential; however, the identities of counsel are matters of public record in the documents cited above.
3. Additional Orrick/other-firm attorneys may have appeared that I could not surface; I have not invented any. If you need the definitive appearance list, the reliable path is the paper docket / archived D. Del. filings for 1999–2001 (the docket sheet itself was cited as an exhibit — "Civil Docket for CA No. 99-0348 … pp. 1-36, Apr. 2005" — in later OGT filings).

Bottom line: Affymetrix's defense was led substantively by Orrick, Herrington & Sutcliffe (William Anthony and Elizabeth Howard) with Sullivan & Cromwell (Michael Steinberg) coordinating, local Delaware counsel of record at Morris Nichols (Jack B. Blumenfeld and Maryellen Noreika), and in-house supervision by GC Vern Norviel with patent counsel Philip McGarrigle.